ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2655

Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment

Eugenio de Miguel1, Irene Monjo 2, Elisa Fernández 3, Diana Peiteado 4, Chamaida Plasencia 5 and Alejandro Balsa 5, 1Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 2FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, 3Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, 5Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: diagnosis, giant cell arteritis, imaging techniques and vasculitis, ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. In the EULAR recommendations of 2018 for the use of imaging in GCA, color Doppler ultrasound (CDUS)  is recognized as the first diagnostic tool to be performed in centers with experience and OMERACT 2018 definitions and reliability of elemental ultrasound lesion of GCA have been published. Today the CDUS of TA is well known and used in clinical practice but the involvement of large vessel vasculitis (LVV) remains underdiagnosed by ultrasound and most of the diagnoses are performed by MRI or PET. In other way, TA halo sign responsiveness to the treatment and apparition in relapses is well know, but the information about this finding is sparse and even in the GiACTA study MRI lack of response in many patients was present. The objective of the present study was to know the frequency, pattern and sensitivity to change of CDUS to detect elemental lesions characteristics of cranial and LVV in patients with GCA diagnosis.

Methods: Observational descriptive study of 148 consecutive patients sent to our fast track clinic with suspicion of GCA. Every patient had a clinical history and a CDUS examination of TA and large vessel (LV) including axilary, subclavian, vertebral and carotid arteries. The OMERACT definitions of halo sign with an hypoechoic wall thickness ≥ 0.34 mm for TA pathology was used for GCA ultrasound diagnosis and for axilary, subclavian and carotids arteries and homogeneous hypoechoic thickness ≥ 1mm of the arterial wall were applied, in vertebral arteries we used a clear halo sign. Atherosclerosis lesions were evaluated to detect this disease as a possible false positive halo sign. The medical records of these patients were reviewed and demographic, physical examination, clinical and laboratory data were collected. The clinical diagnosis based on the evolution of the patient over at least one year was established as the definitive diagnosis.

Results: Of the 148 cases explored 52 had GCA, 34 women, mean age 77.2±7,9 years. The patterns of GCA were: 41 (78.8%) had cranial involvement of TA, with 24 patients with only temporal artery pathology in CDUS and 17 with a mixed patter of TA and LVV. In other way, 28 patients had LVV (53.8%) (17 with TA affectation and 11 with isolated LVV). This means that in our cohort we can see three patterns of GCA affectation: 1) a cranial pattern (affectation of TA) in the 46.1% of cases; 2) a mixed pattern of cranial and LVV affected the 33.3% of the patients and 3) an isolated LVV pattern in the 21.1% of the patients. Mean age of patients with LVV was younger that patients with cranial vasculitis 74 vs. 79 years, with a mean age of mixed pattern of 77 years. In the follow-up we can see as 9 patients with LVV reduce the thickening of the arterial wall below the 1mm cut-off point showing sensitivity to change with the treatment and open the possibility to use ultrasound to measure activity or relapses in GCA LVV.

Conclusion: Ultrasound is an useful tool for the screening GCA including LVV. LVV is very common in our patients (53.8% of GCA cases) and 21.1 % presented only a LVV pattern. LV arteries should be included in the ultrasound examination of GCA suspicions. Ultrasound is sensitive to change in LVV.

Figure 1: Patterns of GCA


Disclosure: E. de Miguel, AbbVie, 2, 5, 8, BMS, 8, BMS, MSD, UCB, Roche, 8, MSD, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 8, UCB, 8; I. Monjo, BMS, 2; E. Fernández, None; D. Peiteado, None; C. Plasencia, None; A. Balsa, BMS, 2, Roche Pharma, 2.

To cite this abstract in AMA style:

de Miguel E, Monjo I, Fernández E, Peiteado D, Plasencia C, Balsa A. Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/large-vessel-vasculitis-diagnosis-is-very-frequent-with-ultrasound-examination-and-shows-responsiveness-to-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/large-vessel-vasculitis-diagnosis-is-very-frequent-with-ultrasound-examination-and-shows-responsiveness-to-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology